Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Protagonist/Takeda’s Hematology Med Makes Mark in PIII
Protagonist Therapeutics and Takeda Pharmaceutical said on March 3 that rusfertide, an investigational therapy for the rare blood disorder polycythemia vera (PV), met the primary endpoint in a global PIII clinical study, VERIFY. The trial covered phlebotomy-dependent patients with PV,…
To read the full story
Related Article
- Takeda Files Polycythemia Vera Drug Rusfertide in US
January 7, 2026
- Takeda Bags Global Rights to Protagonist’s Rare Hematology Asset
February 2, 2024
BUSINESS
- Takeda Rejigs Structure Ahead of CEO Transition, Creates New International Unit
January 30, 2026
- FDA Places Clinical Hold on MPS Gene Therapies: Regenxbio/Nippon Shinyaku
January 30, 2026
- Astellas Positions Izervay as Key Entry Drug in Ophthalmology Push
January 30, 2026
- Chugai Logs Solid 2025 Results on Overseas Growth, Profit Margin Nears 50%
January 30, 2026
- Zynlonta Hits Primary Endpoint in Japanese PI/II Study: Tanabe
January 30, 2026
Japan’s biotech startups are coming under growing pressure as the Tokyo Stock Exchange (TSE) tightens its rules for companies listed…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…